ELI LILLY AND COMPANY Advertising Expense
ELI LILLY AND COMPANY (LLY) reported Advertising Expense of $2.90 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AdvertisingExpense · last filed 2026-02-12
- ELI LILLY AND COMPANY advertising expense for fiscal 2025 was $2.90B, a 107.14% increase from fiscal 2024.
- ELI LILLY AND COMPANY advertising expense for fiscal 2024 was $1.40B, a 27.27% increase from fiscal 2023.
- ELI LILLY AND COMPANY advertising expense for fiscal 2023 was $1.10B, a 13.78% increase from fiscal 2022.
- ELI LILLY AND COMPANY advertising expense for fiscal 2022 was $966.80M, a 22.03% decline from fiscal 2021.
| Period end | Advertising Expense 12 month | Advertising Expense 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.90B 10-K · filed 2026-02-12 | |
| 2024-12-31 | $1.40B 10-K · filed 2026-02-12 | $1.44B 10-K · filed 2025-02-19 |
| 2023-12-31 | $1.10B 10-K · filed 2026-02-12 | $1.12B 10-K · filed 2024-02-21 |
| 2022-12-31 | $966.80M 10-K · filed 2025-02-19 | $1.00B 10-K · filed 2023-02-22 |
| 2021-12-31 | $1.24B 10-K · filed 2024-02-21 | $1.20B 10-K · filed 2022-02-23 |
| 2020-12-31 | $1.10B 10-K · filed 2023-02-22 | |
| 2019-12-31 | $1.10B 10-K · filed 2022-02-23 | |
| 2018-12-31 | $900.00M 10-K · filed 2021-02-17 | |
| 2017-12-31 | $700.00M 10-K · filed 2020-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |